BioCentury
ARTICLE | Company News

CAT, Elan neurological deal

January 25, 2001 8:00 AM UTC

Cambridge Antibody Technology (LSE:CAT) and ELN will discover and develop antibody-based therapeutics to treat neurological disorders. The companies will share 50/50 R&D costs and commercialization pr...